Anika Therapeutics (ANIK) Change in Accured Expenses (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Change in Accured Expenses data on file, last reported at -$1.3 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses rose 56.64% year-over-year to -$1.3 million in Q1 2026; TTM through Mar 2026 was $249000.0, a 106.83% increase from a year earlier, with the FY2025 full-year figure at -$1.5 million, up 59.12% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$1.3 million, down from $141000.0 in the prior quarter.
• Over the last five years, Change in Accured Expenses for ANIK reached as high as $4.6 million in Q3 2023 and fell as low as -$4.3 million in Q2 2023.
• Historically, Change in Accured Expenses has averaged -$311941.2 across 5 years, with a median of -$558000.0 in 2022.
• Across the five-year window, Change in Accured Expenses jumped 255.3% in 2023 and sank 567.67% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at -$558000.0 in 2022, then soared by 231.54% to $734000.0 in 2023, then tumbled by 227.38% to -$935000.0 in 2024, then jumped by 115.08% to $141000.0 in 2025, then sank by 1049.65% to -$1.3 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$1.3 million in Q1 2026, $141000.0 in Q4 2025, and $3.6 million in Q3 2025.